MetaCap

Who Owns Iambic Therapeutics Stock?

NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

13.11-1.15 (-8.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ownership breakdown

Held by institutions
26.21%
Institutional holders
8
  • Institutions 26.2%
  • Insiders 7.6%
  • Public and other 66.2%

Who owns Iambic Therapeutics stock?

Institutional investors own about 26.2% of Iambic Therapeutics's shares, spread across 8 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 7.63% of IAM.

Summary generated from market data by MetaCap's automated system. Methodology

Top mutual fund and ETF holders of IAM

Iambic Therapeutics top fund holders
FundShares% Held
ARK ETF Trust-ARK Genomic Revolution ETF1.35M2.85%

Frequently asked questions

What percentage of Iambic Therapeutics is owned by institutions?

Institutions own about 26.2% of IAM shares and 28.4% of the public float.

How much of Iambic Therapeutics do insiders own?

Insiders, such as officers and directors, own about 7.63% of IAM shares outstanding.

Where does institutional ownership data come from?

Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.

Related